Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
1/12/2023
0:00
15:01
Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ.
Related Content:
More episodes from "JAMA Author Interviews"
Don't miss an episode of “JAMA Author Interviews” and subscribe to it in the GetPodcast app.